Angiogenesis inhibitors are a standard first-line treatment for metastatic colorectal cancer. Anal canal pain is a common adverse event, but its cause has never been described. The aim of the study was to evaluate the association between the use of angiogenesis inhibitors and symptomatic anal ulcer development.
Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients *
Castoro, Carlo;
2018-01-01
Abstract
Angiogenesis inhibitors are a standard first-line treatment for metastatic colorectal cancer. Anal canal pain is a common adverse event, but its cause has never been described. The aim of the study was to evaluate the association between the use of angiogenesis inhibitors and symptomatic anal ulcer development.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
1.57 MB
Formato
Adobe PDF
|
1.57 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
